Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00154219 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Lumiracoxib in Patients With Primary Hip Osteoarthritis
A Phase 3 study of Osteoarthritis, Hip, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,200
- Enrollment target
- 5
- Study locations
NCT00154219 is a Phase 3 study of Osteoarthritis, Hip that has completed, run by Novartis. The registered enrollment target is 1,200 participants, roughly in line with the 1,213-participant average among 20 other Osteoarthritis, Hip trials with a reported enrollment target. The trial reports 5 study locations across 2 states.
The verdict
NCT00154219, a Phase 3 study of Osteoarthritis, Hip, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,200 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy, tolerability, and safety of the investigational drug, lumiracoxib as compared to celecoxib and placebo in subjects with hip osteoarthritis. Both lumiracoxib and celecoxib belong to the same class of drug (COX-2 selective nonsteroidal anti-inflammatory drugs \[NSAIDs\]).
Conditions Studied
Interventions
- DRUG Lumiracoxib (drug)
Study Locations (5)
Other
- Various Sites - Multiple Cities
- Various Sites - Multiple Cities
- Various Sites - Multiple Cities
- Various Sites - Multiple Cities
New Jersey
- For US Site Information, contact Novartis Pharmaceuticals - East Hanover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,200 participants |
| Start Date | 2004-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00154219
The ClinicalTrials.gov registry entry for NCT00154219 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,200 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 1,213-participant average among 20 other Osteoarthritis, Hip trials with a reported enrollment target. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Osteoarthritis, Hip appearing as the primary indexed condition, and to 1 intervention - of which Lumiracoxib (drug) is the first listed.
NCT00154219 reports 5 study locations spanning 2 distinct geographic areas - top geographies include Other, New Jersey.
Frequently Asked Questions
What is clinical trial NCT00154219 about?
NCT00154219 is a clinical study titled "Efficacy and Safety Study of Lumiracoxib in Patients With Primary Hip Osteoarthritis". The purpose of this study is to evaluate the efficacy, tolerability, and safety of the investigational drug, lumiracoxib as compared to celecoxib and placebo in subjects with hip osteoarthritis. Both lumiracoxib and celecoxib belong to the same class of drug (COX-2 selective nonsteroidal anti-inflam...
What is the current status of trial NCT00154219?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,200 participants. The study started on 2004-11.
What conditions does trial NCT00154219 study?
This clinical trial studies the following conditions: Osteoarthritis, Hip.
What interventions are being tested in trial NCT00154219?
The interventions under investigation include: Lumiracoxib (drug) (DRUG).
Who is sponsoring clinical trial NCT00154219?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00154219 being conducted?
This trial has 5 study locations across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoarthritis, Hip
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Naproxen for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip
COMPLETED · Phase 3
-
Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip
COMPLETED · Phase 3
-
Safety and Effectiveness of the HIT Reverse HRS
RECRUITING · NA
-
Perfusion MRI-targeted Joint Embolization for Chronic Musculoskeletal Pain of the Shoulder, Hip and Knee
RECRUITING
-
Non-invasive Evaluation of Upper and Lower Body Function With Showmotion
RECRUITING · NA
-
G7 Acetabular System With Vivacit-E or Longevity Liner PMCF Study
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.